Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-410 in NMIBC
NCT02010203Phase 2Terminated
- Sponsor
- NightHawk Biosciences, Inc.
- Start
- Dec 2013
- Primary completion
- Dec 2017
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of vesigenurtacel-L in bladder cancer, sponsored by NightHawk Biosciences, Inc.. Started Dec 2013; status: terminated.
02
Drugs
vesigenurtacel-L
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT02010203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02010203.